We protect your health through science

Investigation

Immune Pathogenesis and Viral Reservoir

Research Lines

Content with Investigacion Caracterización molecular de los estafilococcus .

Caracterización molecular de los estafilococcus

​El Laboratorio de Referencia e investigación en Infecciones Relacionadas con la Asistencia Sanitaria dispone de un Programa de Vigilancia de Staphylococcus aureus y Estafilococos coagulasa negativa y de la siguiente cartera de servicios:

Estafilococos coagulasa negativa

Identificación:

Por secuencia del gen 16S del ARN ribosómico

Por secuencia del gen rpoB

Por secuencia del gen tuf

 

Marcadores moleculares

Perfil por PFGE

SSC

mec

MLST

 

Detección de genes

Genes mec

Genes de resistencia

Mecanismos de resistencia al linezolid

Dominio V del gen 23S ARNr

Gen rplC (riboproteína L3)

Gen rplD (riboproteína L4)

Gen rplV (riboproteína L22)

 

 

Staphylococcus aureus

Identificación:

PCR del gen Sau

Por secuencia del gen 16S del ARN ribosómico

Por secuencia del gen rpoB

Por secuencia del gen tuf

 

Marcadores moleculares

PFGE

MLST

SSC

mec

Spa-tipo

 

Detección de genes

Genes mec

Gen PVL

Toxinas exfoliativas (SST)

Toxina del Shock Tóxico (TSST)

Research projects

Content with Investigacion Caracterización molecular de los estafilococcus .

  En el Laboratorio de I.R.A.S., también denominado de "Infecciones Intrahospitalarias", nos centramos actualmente en la caracterización molecular de los estafilococos, tanto S. aureus, como coagulasa negativos.

   Los marcadores moleculares habituales, en el caso de los S. aureus son: electroforesis en campo pulsado (PFGE), tipificación multilocus de secuencias (MLST), tipo de casete cromosómico estafilocócico (SSCmec), tipificación spa, También detectamos, entre otros, los genes mec y PVL, los genes que codifican la Toxina exfoliativa (SST) y la Toxina del Shock Tóxico. Asimismo, para la identificación de los estafilococos coagulasa negativos, secuenciamos los genes 16S, rpoBtuf., a los que también aplicamos PFGE, SSCmec, MLST.

   Nuestras líneas de investigación se centran, por un lado, en el estudio de los mecanismos de resistencia a las oxazolidinonas: gen cfr, dominio del gen 23S ARNr , gen rplC (riboproteína L3), gen rplD (riboproteína L4), gen rplV (riboproteína L22). Hemos detectado, por primera vez, la existencia de nuevas mutaciones en la riboproteína L4 en un paciente con fibrosis quística. Aparte de los estudios llevados a cabo de las resistencias al linezolid en distintos hospitales, estudiamos en colaboración con la  Universidad de Tsukuba (Japón) y la Universidad Europea la prevalencia del plásmido pSCFS7 entre cepas cfr positivas de distintos hospitales españoles.

   Por otra parte, participamos en estudios multicéntricos (2002-2014) para conocer mejor el estado de la población estafilocócica española, centrándonos fundamentalmente en las cepas de S. aureus resistentes a meticilina (SARM); dado que es un importante patógeno humano que causa una amplia variedad de infecciones que pueden ser leves, como  algunas infecciones de piel y partes blandas, o graves, como bacteriemia, endocarditis, neumonía e infecciones de localización quirúrgica. Además, pueden producir una colonización asintomática, lo que facilita su transmisión y diseminación. Desde su descripción  inicial en 1959 y durante varias décadas, el SARM se había considerado un patógeno confinado al ámbito sanitario, pero a partir de la década de los noventa, se describe la emergencia de cepas SARM responsables de infecciones aparentemente adquiridas en la comunidad.

Dentro de esta línea estamos colaborando en el proyecto: "Colonización por S. aureus resistente a la meticilina en niños sanos de la comunidad (estudio C.O.S.A.C.O.)", que es un estudio multicéntrico de ámbito nacional.

También colaboramos con otros laboratorios en distintos estudios, como: "Mecanismos de patogenicidad y protección en bacterias Gram positivas causantes de enfermedades respiratorias y bacteriemia". 

Publications

Sort
Category

Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding

Valdezate S, Medina-Pascual MJ, Villalón P, Garrido N, Monzón S, Cuesta I, Cobo F (2024). Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding. J Antimicrobial Chem. 2024 Jul 1;79(7):1683-1687

PUBMED DOI

Hookworm secreted extracellular vesicles interact with host cells and prevent inducible colitis in mice.

Eichenberger RM, Ryan S, Jones L, Buitrago G, Polster R, Montes de Oca M, Zuvelek J, Giacomin PR, Dent LA, Engwerda CR, Field MA, Sotillo J, Loukas A. Hookworm secreted extracellular vesicles interact with host cells and prevent inducible colitis in mice. Front Immunol. 2018 Apr 30;9:850.

PUBMED DOI

StaR Is a positive regulator of topoisomerase I activity involved in supercoiling maintenance in Streptococcus pneumoniae

de Vasconcelos Junior AA, Tirado-Vélez JM, Martín-Galiano AJ, Megias D, Ferrándiz MJ, Hernández P, Amblar M, de la Campa AG. Int J Mol Sci. 2023; 24:5973.

PUBMED DOI

Toll-like receptor signaling-deficient cells enhance antitumor activity of cell-based immunotherapy by increasing tumor homing

A. Morales-Molina, M.A. Rodríguez-Milla, S,. Gambera, T. Cejalvo, B. de Andrés M.L. Gaspar, J. Garcia-Castro. Cancer Res Commun 2023 Mar 1;3(3):347-360. eCollection 2023 Mar

PUBMED DOI

Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread.

1. Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread. Dahdouh E, Gómez-Marcos L, Cañada-García JE, de Arellano ER, Sánchez-García A, Sánchez-Romero I, López-Urrutia L, de la Iglesia P, Gonzalez-Praetorius A, Sotelo J, Valle-Millares D, Alonso-González I, Bautista V, Lara N, García-Cobos S, Cercenado E, Aracil B, Oteo-Iglesias J, Pérez-Vázquez M; Spanish Eco-Carba Study Group. Revista: Front Cell Infect Microbiol 2024 May 16;14:1390966.

PUBMED DOI

The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios

Sanchez-Merino V, Martin-Serrano M, Beltran M, Lazaro-Martin B, Cervantes E, Oltra M, Sainz T, Garcia F, Navarro ML, Yuste E; Vaccines (Basel). 2023 Dec 20;12(1):8;

PUBMED DOI

The sulfur-related metabolic status of Aspergillus fumigatus during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target

Alharthi R, Sueiro-Olivares M, Storer I, Bin Shuraym H, Scott J, Al-Shidhani R, Fortune-Grant R, Bignell E, Tabernero L, Bromley M and Amich J. 2025. Virulence, 16(1):2449075

PUBMED DOI

The importance of microbiology reference laboratories and adequate funding for infectious disease surveillance

Shaw D, Torreblanca RA, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Casanova C, Choi EH, Claus H, Corcoran M, Cottrell S, Cunney R, Cuypers L, Dalby T, Davies H, de Gouveia L, Deghmane AE, Desmet S, Domenech M, Drew R, Plessis MD, Duarte C, Fuursted K, Golden A, Almeida SCG, Henares D, Henriques-Normark B, Hilty M, Hoffmann S, Humphreys H, Jacobsson S, Johnson C, Jolley KA, Kawabata A, Kozakova J, Kristinsson KG, Krizova P, Kuch A, Ladhani S, Lâm TT, Ayala MEL, Lindholm L, Litt D, Maiden MCJ, Martin I, Martiny D, Mattheus W, McCarthy ND, Meehan M, Meiring S, Mölling P, Morfeldt E, Morgan J, Mulhall R, Muñoz-Almagro C, Murdoch D, Musilek M, Novakova L, Oftadeh S, Perez-Arguello A, Pérez-Vázquez MD, Perrin M, Prevost B, Roberts M, Rokney A, Ron M, Sanabria OM, Scott KJ, Sempere J, Siira L, de Lemos APS, Sintchenko V, Skoczyńska A, Slotved HC, Smith AJ, Taha MK, Toropainen M, Tzanakaki G, Vainio A, van der Linden MPG, van Sorge NM, Varon E, Moreno JV, Vohrnova S, von Gottberg A, Yuste J, Brueggemann AB. Lancet Digit Health. 2025 Apr;7(4):e275-e281.

PUBMED DOI

ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.

2. Aragoneses-Fenoll L, Montes-CasadoM, Ojeda G, Acosta YY, Herranz J, Martínez S, Blanco-Aparicio C, Criado G, Pastor J, Dianzani U, Portolés P, Rojo JM. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem. Pharmacol. 2016 Apr 15;106:56-69. Epub 2016 Feb 13.

PUBMED DOI

Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.

5. Mas V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terron MC, et al. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog. 2016;12(9):e1005859.

PUBMED DOI

Godet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018 ​

Godet C, Alastruey-Izquierdo A, Flick H, Hennequin C, Mikilps-Mikgelbs R, Munteanu O, Page I, Seidel D, Salzer HJF. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother. 2018 Feb 1;73(2):280-286. doi: 10.1093/jac/dkx390. PMID: 29126309.​

PUBMED DOI

Ultrastructure of the Babesia divergens free merozoite

Terrón M.C, González-Camacho F., González L.M., Luque D.*, Montero E. 2016. Ultrastructure of the Babesia divergens free merozoite. Ticks Tick Borne Diseases. 7(6):1274-1279. *Corresponding author. IF: 3.23, Q1.

PUBMED DOI

Exploring the genetic background of the botulism neurotoxin BoNT/B2 in Spain

Valdezate S, Carrasco G, Medina MJ, Garrido N, Del Pino S, Valiente M, Pallarés MP, Villalon P. (2023). Exploring the genetic background of the botulism neurotoxin BoNT/B2 in Spain. Microbiol Spectr. Sep 26;11(5):e0238023

PUBMED DOI

HDP2: a ribosomal DNA (NTS-ETS) sequence as a target for species-specific molecular diagnosis of intestinal taeniasis in humans.

Flores MD, Gonzalez LM, Hurtado C, Motta YM, Domínguez-Hidalgo C, Merino FJ, Perteguer MJ, Gárate T. HDP2: a ribosomal DNA (NTS-ETS) sequence as a target for species-specific molecular diagnosis of intestinal taeniasis in humans. Parasit Vectors. 2018 Feb 27;11(1):117. doi: 10.1186/s13071-018-2646-6.

PUBMED DOI

The balance between gyrase and topoisomerase I activities determines levels of supercoiling, nucleoid compaction, and viability in bacteria

García-López M, Megias D, Ferrándiz MJ, de la Campa AG. Front Microbiol. 2023; 11;1094692.

PUBMED DOI

Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice

Isidro-Hernández M, Casado-García A, Oak N, Alemán-Arteaga S, Ruiz-Corzo B, Martínez-Cano J, Mayado A, G. Sánchez E, Blanco O, Gaspar ML, Orfao A, Alonso-López D, De las Rivas J, Riesco S, Prieto-Matos P, González-Murilo A, García Criado FJ, García Cenador MB, Ramírez-Orellana M, De Andrés B, Vicente-Dueñas C, Cobaleda C, Nichols KE, Sánchez-García I. Nat Commun 2023 Aug 24;14(1):5159.

PUBMED DOI

Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak.

2. Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak. Autores: Ramírez de Arellano E, Saavedra-Lozano J, Villalón P, Jové-Blanco A, Grandioso D, Sotelo J, Gamell A, González-López JJ, Cervantes E, Gónzalez MJ, Rello-Saltor V, Esteva C, Sanz-Santaeufemia F, Yagüe G, Manzanares Á, Brañas P, Ruiz de Gopegui E, Carrasco-Colom J, García F, Cercenado E, Mellado I, Del Castillo E, Pérez-Vazquez M, Oteo-Iglesias J, Calvo C; Spanish PedGAS-Net/CIBERINFEC GAS Study Group. Revista: mSphere. 2024 Mar 26;9(3):e0072923.

PUBMED DOI

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses

Beltran-Pavez C, Bontjer I, Gonzalez N, Pernas M, Merino-Mansilla A, Olvera A, Miro JM, Brander C, Alcami J, Sanders RW, Sanchez-Merino V, Yuste E; J Virol. 2022 Jan 12;96(1):e0134321.

PUBMED DOI

Fungal burden assessment in hospital zones with different protection degrees

García-Gutiérrez L, Baena Rojas B, Ruiz M, Hernández Egido S, Ruiz-Gaitán AC, Laiz L, Pemán J, Cuétara-García MS, Mellado E & Martin-Sanchez PM. Build Environ, Volume 269, 1 February 2025, 112454

DOI

Antimicrobial resistance and epidemiological aspects of Neisseria gonorrhoeae in the province of Lleida, Spain (2017-2024).

Cumplido A, Aramburu J, Font M, Montes M, Abad R, López E, Bernet A, Mormeneo S, Prats I, García M, Sánchez E, Bellés A. Enferm Infecc Microbiol Clin (Engl Ed). 2025 Mar;43(3):156-161.

PUBMED DOI

Content with Investigacion Caracterización molecular de los estafilococcus .

List of staff

Additional Information

Contact Information

María Teresa Coiras

918223782
mcoiras@isciii.es

generic email: pirv.isciii@gmail.com

 

Scientific Societies

 

•    Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
•    AIDS Study Group (GeSIDA) of SEIMC.
•    PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).

 

Other links

 

You can follow the activity of our group in Twitter (X), Instagram and Linkedin.

 

Collaboration in other projects

Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections.  Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545

Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024

Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924

Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025

Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715

Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006

Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22

Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5

Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006

Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877

Contact Information

María Teresa Coiras

918223782
mcoiras@isciii.es

generic email: pirv.isciii@gmail.com

 

Scientific Societies

 

•    Spanis Society for Infectious Diseases and Clinical Microbiology (SEIMC).
•    AIDS Study Group (GeSIDA) of SEIMC.
•    PIRV is member of the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC, group CB21/13/00015).

 

Other links

 

You can follow the activity of our group in Twitter (X), Instagram and Linkedin.

 

Collaboration in other projects

Project Title: Rectal microbiota as a factor associated with vulnerability to repeated sexually transmitted infections.  Microsex Studio
Principal investigators: Vicente Estrada Pérez (San Carlos Clinical Hospital)
Financing agency: Strategic Action in Health (AES) 2023
Participating entities: San Carlos Clinical Hospital, ISCIII
Duration: 01/01/2024-12/31/2026. Contract/project file: PI23/01545

Project title: Prospective, observational, longitudinal, multicenter study to evaluate clinical efficacy, safety and immunogenicity developed in individuals with Philadelphia-negative Chronic Myeloproliferative Neoplasms treated with JAK inhibitors after receiving full vaccination with Adjuvanted Herpes Zoster Subunit vaccine (Shingrix)
Principal investigators: Valentín García Gutiérrez (Hospital Univ Ramón y Cajal)
Funding agency: GSK Glaxo Smithkline
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024 – 12/31/2024

Project title: Infection in Solid Organ Transplant recipients: correlation with immune function. Identification of predictive biomarkers and feasibility evaluation with CD45RAneg cell therapy
Principal investigators: Alejandro Luna de Abia, Jesús Fortún (Univ Ramón y Cajal Hospital)
Financing agency: Strategic Health Action (AES) 2023
Participating entities: IRYCIS, ISCIII
Duration: 01/01/2024-12/31/2026
Contract/project file: PI23/01924

Project title: Evaluation of the levels of the System associated with BLyS in patients with post-infectious syndromes and dysautonomic alterations of the heart rhythm
Principal researcher: Pablo Guisado
Funding agency: Spanish Society of Internal Medicine SEMI.
Participating entities: ISCIII, Quironsalud Research Institute for Research and Innovation
Duration 2023-2025

Project title: HIV Open Science (dissemination project)
Principal researcher: Eva Poveda
Financing agency: Spanish Foundation for Science and Technology (FECYT), Call for aid for the Promotion of Scientific, Technological and Innovation Culture.
Participating entities: ISCIII, Fundación Biomédica Galicia Sur, IrsiCaixa, Hospital Vall d’Hebron, Hospital de la Princesa, Fundación Imagina Más, Institute of Biomedicine of Seville (IBIS), Case Western Reserve University (Cleveland, Ohio)
Duration 2023-2024
Contract/project file: 17715

Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV (Annual renewal).
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2023 – 04/01/2024
Contract/project file: 1,013,006

Project title: Clinical and microbiological impact of the monkeypox virus outbreak in patients in Spain (2022): multicenter project MONKPOX-ESP22, Work package 4, virological research.
Principal researcher: Anabel Negredo (WP4 coordinator); Maria Paz Sánchez Seco (general coordinator)
Financing agency: CIBERINFEC/CIBERESP ISCIII Strategic Action.
Participating entities: ISCIII
Duration July 2022 - May 2023
Contract/project file: MONKPOX-ESP22

Project title: Biomarkers and underlying immunopathological mechanisms of post COVID-19 condition.
Principal investigator: Gemma Moncunill Piñas (IP); Marta Massanella (coIP); María Teresa Coiras López (co-PI)
Financing agency: CIBERINFEC Strategic Action.
Participating entities: ISCIII, IS-Global, IrsiCaixa
Duration 07/28/2022-07/29/2024
Contract/project file: IM22/INF/5

Project title: Identification of immunological biomarkers associated with the cellular and humoral immune response related to vaccination against SARS-CoV-2 in patients with HIV.
Principal investigator: Rafael Rodríguez Rosado
Funding agency: Alfonso X El Sabio University-Santander Universities. XIII Call for Research Projects.
Participating entities: ISCIII, Severo Ochoa University Hospital
Duration 04/01/2022 – 04/01/2023
Contract/project file: 1,013,006

Project title: Characterization of the immune response developed after vaccination with COVID-19 in patients with hematological malignancies.
Principal researcher: Valentín García Gutiérrez
Funding agency: Ministry of Science and Innovation, PI21 - Health research projects (AES 2021). Health research project modality.
Participating entities: ISCIII, Ramón y Cajal University Hospital
Duration 01/01/2022 – 12/31/2024
Contract/project file: PI21_00877

Content with Investigacion Caracterización molecular de los estafilococcus .